Supernus Pharmaceuticals
SUPN
209 hedge funds and large institutions have $604M invested in Supernus Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 86 increasing their positions, 56 reducing their positions, and 23 closing their positions.
109% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 23
54% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 56
13% more funds holding
Funds holding: 185 → 209 (+24)
1% more call options, than puts
Call options by funds: $2.37M | Put options by funds: $2.35M
8% less capital invested
Capital invested by funds: $659M → $604M (-$55.4M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
Top Sellers
SUPN Hedge Fund Activity: Q4 2015 in Review
209 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2015, worth a combined $604M — down 8.4% from $659M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new SUPN positions and 23 closed out — a net gain of 25 holders — while 86 added to existing stakes and 56 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $14.1M. The largest seller was NEA Management Company, exiting entirely with an estimated $107M sold.
- 209 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2015, up from 185 in Q3 2015.
- Funds reported $604M of Supernus Pharmaceuticals stock for Q4 2015, down 8.4% quarter-over-quarter.
- 48 funds opened new Supernus Pharmaceuticals positions in Q4 2015 and 23 closed out, a net change of +25 holders.
- The largest Supernus Pharmaceuticals buyer in Q4 2015 was Acadian Asset Management, an estimated $14.1M added.
- The largest Supernus Pharmaceuticals seller in Q4 2015 was NEA Management Company, an estimated $107M sold.
Based on aggregated 13F filings for Q4 2015.